Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and thiophenes

rosiglitazone has been researched along with thiophenes in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's8 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anglard, P; Bonnafous, S; Chavey, C; Mari, B; Monthouel, MN; Tartare-Deckert, S; Van Obberghen, E1
Chae, YN; Choi, SH; Kim, HS; Kim, JG; Kim, JK; Kim, MK; Kim, SH; Lee, CH; Lim, JI; Moon, HS; Park, SK; Shin, CY; Shin, YA; Son, MH1
Guo, HF; Li, D; Li, ZR; Liu, ZY; Shao, H; Si, SY; Yang, Y; Yang, Z1
Bae, MH; Chae, YN; Choi, HH; Choi, SH; Hur, Y; Kim, E; Kim, JG; Kim, MK; Lim, JI; Moon, HS; Park, CS; Park, YH; Shin, CY; Son, MH1
Basu, S; Giri, S; Gite, A; Godha, A; Goswami, A; Jain, M; Patel, P; Pingali, H; Raval, P; Raval, S; Shah, M; Suthar, D1
He, X; Jiang, Q; Jiang, W; Li, Z; Liu, Z; Lu, X; Shao, H; Si, S; Xu, Y; Yang, Y; Zhang, H; Zhao, B; Zheng, Z1
Wilding, JP1
Atar, D; Serebruany, VL1
Fang, X; Fung, ML; Huang, Y; Liu, Y; Mao, G; Shyy, JY; Tian, XY; Wang, N1
Agarwal, AK; Garg, A; Sankella, S1

Reviews

1 review(s) available for rosiglitazone and thiophenes

ArticleYear
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:11

    Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome

2012

Other Studies

9 other study(ies) available for rosiglitazone and thiophenes

ArticleYear
Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.
    The Journal of biological chemistry, 2003, Apr-04, Volume: 278, Issue:14

    Topics: Adipocytes; Animals; Blood Vessels; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Diet; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Male; Matrix Metalloproteinase 12; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Matrix Metalloproteinases, Membrane-Associated; Matrix Metalloproteinases, Secreted; Metalloendopeptidases; Mice; Mice, Inbred AKR; Mice, Inbred C57BL; Mice, Obese; Mitosis; Obesity; Phenylalanine; Protease Inhibitors; RNA, Messenger; Rosiglitazone; Stromal Cells; Thiazoles; Thiazolidinediones; Thiophenes; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-3

2003
PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Archives of pharmacal research, 2009, Volume: 32, Issue:5

    Topics: Adipogenesis; Administration, Oral; Animals; Blood Glucose; Blood Volume; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Partial Agonism; Genes, Reporter; Humans; Hypoglycemic Agents; Isoxazoles; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred ICR; PPAR gamma; Propionates; Rosiglitazone; Thiazolidinediones; Thiophenes; Transfection; Water-Electrolyte Balance

2009
The effect of substituted thiophene and benzothiophene derivates on PPARgamma expression and glucose metabolism.
    Journal of enzyme inhibition and medicinal chemistry, 2010, Volume: 25, Issue:2

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glucose Tolerance Test; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Mice; Mice, Inbred NOD; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Transcriptional Activation

2010
PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    European journal of pharmacology, 2011, Jan-15, Volume: 650, Issue:2-3

    Topics: 3T3-L1 Cells; Adipocytes; Animals; Cells, Cultured; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Phenylpropionates; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Water-Electrolyte Balance

2011
Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
    Bioorganic & medicinal chemistry letters, 2011, May-15, Volume: 21, Issue:10

    Topics: Administration, Oral; Animals; Cell Line; Dose-Response Relationship, Drug; Hypoglycemic Agents; Inhibitory Concentration 50; Mice; Molecular Structure; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Binding; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Thiophenes

2011
Two thiophenes compounds are partial peroxisome proliferator-activated receptor α/γ dual agonists.
    Biological & pharmaceutical bulletin, 2011, Volume: 34, Issue:10

    Topics: Animals; Cell Culture Techniques; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Genes, Reporter; Hepatocytes; Humans; Hypoglycemic Agents; Mice; Molecular Targeted Therapy; Plasmids; PPAR alpha; PPAR gamma; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfoxides; Thenoyltrifluoroacetone; Thiazolidinediones; Thiophenes

2011
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor

2012
Peroxisome proliferator-activated receptor-γ ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor.
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 60, Issue:6

    Topics: Animals; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Hypoxia; Indoles; Monocrotaline; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Pulmonary Artery; Receptor, Serotonin, 5-HT2B; Rosiglitazone; Serotonin 5-HT2 Receptor Agonists; Thiazolidinediones; Thiophenes; Transcription Factor AP-1; Up-Regulation

2012
Characterization of the Mouse and Human Monoacylglycerol O-Acyltransferase 1 (Mogat1) Promoter in Human Kidney Proximal Tubule and Rat Liver Cells.
    PloS one, 2016, Volume: 11, Issue:9

    Topics: Acyltransferases; Anilides; Animals; Blotting, Northern; Caco-2 Cells; Cell Line; Cell Line, Tumor; Chromatin Immunoprecipitation; Computational Biology; HT29 Cells; Humans; Kidney Tubules, Proximal; Liver; Mice; Oxazoles; PPAR alpha; Promoter Regions, Genetic; Pyrimidines; Rats; Real-Time Polymerase Chain Reaction; Rosiglitazone; Sulfones; Thiazoles; Thiazolidinediones; Thiophenes; Tyrosine

2016